Abbott Laboratories Stock Performance
Abbott Laboratories shares trade at $104.57, sitting marginally below the 50-day moving average of $104.70 but above the 200-day moving average of $101.83, per SID market data. The stock has gained 1.67% over the past month, though the three-month return stands at negative 2.81%, and the trailing twelve-month performance reflects a decline of 18.83%. The 14-day relative strength index registers at 61.9, indicating momentum that is approaching but has not yet reached overbought territory. ABT carries a beta of 0.751, according to Massive/Polygon data, confirming its historically lower volatility relative to the broader market — a characteristic common among large-cap healthcare names. Average daily trading volume sits at approximately 8.88 million shares, supporting adequate liquidity for institutional participants. The company's market capitalization currently stands at approximately $202.5 billion, positioning it among the largest diversified medical device and diagnostics firms globally.
Abbott Laboratories Valuation Analysis
Abbott Laboratories trades at a price-to-earnings ratio of 31.15, per SID market data, which represents a premium to the broader healthcare sector average. The price-to-book ratio stands at 3.90, according to SEC filings, reflecting the market's valuation of Abbott's intangible assets including its extensive medical device and diagnostics intellectual property portfolio. The PEG ratio is reported at negative 0.58, a figure that signals a disconnect between the current earnings multiple and projected growth rates. Abbott offers a dividend yield of 2.06%, underscoring its status as a Dividend Aristocrat with a decades-long track record of consecutive annual dividend increases. The company's $202.5 billion market capitalization places it at a valuation level where investors are paying a meaningful premium for the stability and diversification of Abbott's four-segment business model spanning diagnostics, medical devices, nutrition, and established pharmaceuticals.
Smart Money Activity for ABT
Abbott Laboratories registers a smart money score of 51 out of 100, reflecting a neutral overall positioning among sophisticated market participants, per SID market data. Institutional ownership scores a perfect 25 out of 25, indicating robust and sustained interest from large fund managers as documented in 13F institutional filings. In contrast, insider activity scores 12.3 out of 25, with SEC Form 4 filings revealing 17 insider transactions over the past 90 days — comprising 7 purchases and 10 sales. The net selling bias among insiders is notable, though such activity can often reflect routine compensation-related dispositions rather than directional conviction. Dark pool activity registers at 8.5 out of 25, suggesting relatively subdued off-exchange institutional trading. Congressional trading activity scores 5.3 out of 25, indicating limited recent engagement by members of Congress. The divergence between the maximum institutional score and the more modest insider and dark pool readings produces the balanced overall neutral signal.
Abbott Laboratories Earnings Outlook
Abbott Laboratories has demonstrated consistent earnings execution across recent quarters, per company earnings reports. In the most recent reported quarter, Abbott posted earnings per share of $1.42, matching the consensus analyst estimate precisely and registering zero surprise. The preceding quarter delivered EPS of $1.31 against an estimate of $1.28, representing a positive surprise of $0.03, while the quarter before that produced EPS of $1.15 versus a $1.14 estimate, a $0.01 beat. This pattern reflects a sequential earnings acceleration from $1.15 to $1.31 to $1.42 across three consecutive quarters, representing approximately 23.5% growth over that span. Analyst estimates for the upcoming quarter project EPS of $1.42, flat with the most recent result. Abbott's ability to meet or exceed consensus expectations in each of the last three reported periods underscores the company's operational predictability, a trait valued by institutional investors in the healthcare sector.
Wall Street Analyst Ratings for ABT
Wall Street consensus on Abbott Laboratories remains predominantly constructive, though a recent downgrade introduces a more cautious perspective, per Wall Street analyst reports. On October 27, Argus Research downgraded ABT from Buy to Hold, marking the most notable rating change in the current cycle. However, this stands in contrast to multiple reaffirmations of positive ratings issued the same week. Wells Fargo maintained its Overweight rating on October 23, while TD Cowen reiterated a Buy rating on October 22. JP Morgan also maintained its Overweight classification on October 22, and Baird reaffirmed an Outperform rating on the same date. Per SID consensus data, four of the five most recent analyst actions maintain bullish or overweight stances, with only Argus Research adopting a neutral position. The cluster of maintained positive ratings following Abbott's earnings results suggests that the majority of sell-side analysts view the company's fundamental trajectory as intact despite the stock's 18.83% year-over-year decline.
